Table 2.
Cytogenetics
| Variable | De novo disease Number, no. (%*) | Therapy-related disease Number, no. (%*) | p value |
|---|---|---|---|
| AML cytogenetics† | |||
| Number of patients | 308 (100) | 21 (100) | |
| Favorable | 45 (15) | 2 (10) | 0.8 |
| t(8;21) | 5 (5) | 0 (0) | |
| inv(16) or t(16;16) | 18 (6) | 0 (0) | |
| t(15;17) | 12 (4) | 2 (10) | |
| Intermediate | 186 (60) | 11 (52) | 0.5 |
| Normal | 119 (39) | 5 (24) | |
| +8 | 17 (6) | 0 (0) | |
| del(9q) | 4 (1) | 0 (0) | |
| Abnormality of 11q23 | 2 (4) | 2 (10) | |
| t(9;22) | 4 (1) | 0 (0) | |
| t(6;9) | 4 (1) | 0 (0) | |
| Other | 26 (8) | 4 (19) | |
| Adverse | 42 (14) | 7 (33) | 0.024 |
| −5, del(5q), or −7 | 16 (5) | 3 (14) | |
| Abnormal 3q | 1 (0) | 0 (0) | |
| Complex | 25 (8) | 4 (19) | |
| Not obtained/not available | 35 (11) | 1 (5) | 0.1 |
| MDS and mAML cytogenetics‡ | |||
| Number of patients | 168 (100) | 59 (100) | |
| Favorable MDS | 82 (49) | 7 (12) | <0.0001 |
| 5q- | 2 (1) | 0 (0) | |
| 20q- | 1 (1) | 0 (0) | |
| Y- | 0 (0) | 0 (0) | |
| Normal | 79 (47) | 7 (12) | |
| Intermediate MDS | 37 (22) | 6 (10) | 0.12 |
| All others | 37 (22) | 6 (10) | |
| Adverse MDS | 38 (23) | 41 (69) | <0.0001 |
| Abnormal 7 | 11 (7) | 16 (27) | |
| Complex | 27 (16) | 25 (42) | |
| Not obtained/not available | 11 (7) | 5 (8) | 0.6 |
*
Percentages may not add to 100 because of rounding
†
Classified according to MRC grouping scheme
‡
Classified according to the IPSS grouping scheme